Identification Name Pemetrexed Accession Number DB00642 (APRD00573, EXPT02075) Type Small Molecule Groups Approved, Investigational Description Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
Structure Synonyms Not Available External IDs LY-231514 / LY231514 / NSC-698037 Product Ingredients Approved Prescription Products Name Dosage Strength Route Labeller Marketing Start Marketing End Act Pemetrexed Powder, for solution 100 mg Intravenous Actavis Pharma Company Not applicable Not applicable Canada Act Pemetrexed Powder, for solution 500 mg Intravenous Actavis Pharma Company Not applicable Not applicable Canada Act Pemetrexed Powder, for solution 1000 mg Intravenous Actavis Pharma Company Not applicable Not applicable Canada Alimta Injection, powder, lyophilized, for solution 100 mg/4mL Intravenous Eli Lilly & Co. Ltd. 2007-09-07 Not applicable US Alimta Powder, for solution 500 mg Intravenous Eli Lilly & Co. Ltd. 2004-08-03 Not applicable Canada Alimta Injection, powder, for solution 500 mg Intravenous Eli Lilly Nederland B.V. 2004-09-20 Not applicable EU Alimta Injection, powder, lyophilized, for solution 500 mg/20mL Intravenous Eli Lilly & Co. Ltd. 2004-02-04 Not applicable US Alimta Powder, for solution 100 mg Intravenous Eli Lilly & Co. Ltd. 2009-01-09 Not applicable Canada Alimta Injection, powder, for solution 100 mg Intravenous Eli Lilly Nederland B.V. 2004-09-20 Not applicable EU Pemetrexed Powder, for solution 500 mg Intravenous Apotex Corporation Not applicable Not applicable Canada Pemetrexed Powder, for solution 100 mg Intravenous Apotex Corporation Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 500 mg Intravenous Accord Healthcare Limited 2017-05-29 Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 100 mg Intravenous Teva Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 100 mg Intravenous Sandoz Canada Incorporated Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 1000 mg Intravenous Pfizer Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 500 mg Intravenous Sandoz Canada Incorporated Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 100 mg Intravenous Pfizer Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 100 mg Intravenous Accord Healthcare Limited 2017-05-24 Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 500 mg Intravenous Teva Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 1000 mg Intravenous Sandoz Canada Incorporated Not applicable Not applicable Canada Pemetrexed Disodium for Injection Powder, for solution 500 mg Intravenous Pfizer Not applicable Not applicable Canada Pemetrexed for Injection Powder, for solution 100 mg Intravenous Dr Reddy's Laboratories Not applicable Not applicable Canada Pemetrexed for Injection Powder, for solution 500 mg Intravenous Dr Reddy's Laboratories Not applicable Not applicable Canada Taro-pemetrexed Powder, for solution 500 mg Intravenous Taro Pharmaceuticals, Inc. 2017-02-15 Not applicable Canada Taro-pemetrexed Powder, for solution 100 mg Intravenous Taro Pharmaceuticals, Inc. Not applicable Not applicable Canada
Approved Generic Prescription Products Name Dosage Strength Route Labeller Marketing Start Marketing End Ciambra Injection, powder, for solution 100 mg Intravenous Menarini International Operations Luxembourg S.A. 2015-12-02 Not applicable EU Ciambra Injection, powder, for solution 500 mg Intravenous Menarini International Operations Luxembourg S.A. 2015-12-02 Not applicable EU Pemetrexed Accord Solution for Infusion Powder, for solution 1000 mg Intravenous Accord Healthcare Limited 2016-01-18 Not applicable EU Pemetrexed Hospira Injection, powder, for solution 100 mg Intravenous Hospira, Inc. 2015-11-20 Not applicable EU Pemetrexed Hospira Injection, powder, for solution 500 mg Intravenous Hospira, Inc. 2015-11-20 Not applicable EU Pemetrexed Hospira Injection, powder, for solution 000 mg Intravenous Hospira, Inc. 2015-11-20 Not applicable EU Pemetrexed Lilly Injection, powder, for solution 100 mg Intravenous Eli Lilly Netherlands 2015-09-14 Not applicable EU Pemetrexed Lilly Injection, powder, for solution 500 mg Intravenous Eli Lilly Netherlands 2015-09-14 Not applicable EU Pemetrexed Medac Injection, powder, for solution 100 mg Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2015-11-27 Not applicable EU Pemetrexed Medac Injection, powder, for solution 1000 mg Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2015-11-27 Not applicable EU Pemetrexed Medac Injection, powder, for solution 500 mg Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2015-11-27 Not applicable EU Pemetrexed Sandoz Powder, for solution 1000 mg Intravenous Sandoz 2015-09-18 Not applicable EU Pemetrexed Sandoz Injection, powder, for solution 500 mg Intravenous Sandoz 2015-09-18 Not applicable EU Pemetrexed Sandoz Injection, powder, for solution 100 mg Intravenous Sandoz 2015-09-18 Not applicable EU
Approved Over the Counter Products Not Available Unapproved/Other Products Not Available International Brands Not Available Brand mixtures Not Available Categories UNII 04Q9AIZ7NO CAS number 137281-23-3 Weight Average: 427.4106 Chemical Formula C20 H21 N5 O6 InChI Key WBXPDJSOTKVWSJ-ZDUSSCGKSA-N InChI InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
IUPAC Name (2S)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
SMILES [H][
[email protected] @](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Pharmacology Indication Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Structured Indications Pharmacodynamics Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.
Mechanism of action Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.
Target Kind Pharmacological action Actions Organism UniProt ID Thymidylate synthase Protein yes inhibitor
Human P04818 details Bifunctional purine biosynthesis protein PURH Protein yes inhibitor
Human P31939 details Dihydrofolate reductase Protein yes inhibitor
Human P00374 details Trifunctional purine biosynthetic protein adenosine-3 Protein yes inhibitor
Human P22102 details
Related Articles
Absorption Not Available Volume of distribution
Protein binding 81%
Metabolism
Metabolized by Cytochrome P450 Enzymes
Route of elimination Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.
Half life 3.5 hours
Clearance
91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]
Toxicity Not Available Affected organisms Pathways Not Available Pharmacogenomic Effects/ADRs Not Available Interactions Drug Interactions Drug Interaction Drug group Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed. Approved BCG vaccine The therapeutic efficacy of Bcg can be decreased when used in combination with Pemetrexed. Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Pemetrexed. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed. Approved Clozapine The risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine. Approved Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Pemetrexed. Approved, Investigational Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Pemetrexed. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Pemetrexed. Approved Digoxin Digoxin may decrease the cardiotoxic activities of Pemetrexed. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed. Approved, Investigational Fingolimod Pemetrexed may increase the immunosuppressive activities of Fingolimod. Approved, Investigational G17DT The risk or severity of adverse effects can be increased when Pemetrexed is combined with G17DT. Investigational GI-5005 The risk or severity of adverse effects can be increased when Pemetrexed is combined with GI-5005. Investigational INGN 201 The risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 225. Investigational Leflunomide The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide. Approved, Investigational Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Pemetrexed. Withdrawn Natalizumab The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab. Approved, Investigational Oleandrin Anvirzel may decrease the cardiotoxic activities of Pemetrexed. Experimental Ouabain Ouabain may decrease the cardiotoxic activities of Pemetrexed. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed. Approved, Investigational Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Pemetrexed is combined with Rabies vaccine. Approved Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Pemetrexed. Approved Rindopepimut The risk or severity of adverse effects can be increased when Pemetrexed is combined with CDX-110. Investigational Roflumilast Roflumilast may increase the immunosuppressive activities of Pemetrexed. Approved Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed. Approved SRP 299 The risk or severity of adverse effects can be increased when Pemetrexed is combined with SRP 299. Investigational Tacrolimus The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Pemetrexed is combined with TG4010. Investigational Tofacitinib Pemetrexed may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Pemetrexed. Approved, Investigational
Food Interactions Not Available References Synthesis Reference US5344932 General References Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. [PubMed:16291410 ] Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic]. Bull Cancer. 2007;94 Spec No Actualites:S134-8. [PubMed:17845983 ] Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. [PubMed:20446853 ] Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. [PubMed:12722874 ] External Links ATC Codes L01BA04 — Pemetrexed AHFS Codes PDB Entries FDA label Download (233 KB) MSDS Not Available Clinical Trials Clinical Trials Phase Status Purpose Conditions Count 0 Active Not Recruiting Treatment Brain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Metastatic Cancers / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis / Unspecified Adult Solid Tumor, Protocol Specific 1 0 Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 1 Active Not Recruiting Treatment Adenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer 1 1 Active Not Recruiting Treatment Advanced Cancers 1 1 Active Not Recruiting Treatment Cancers 2 1 Active Not Recruiting Treatment Malignant Pleural Mesothelioma (MPM) 1 1 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 3 1 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid 1 1 Active Not Recruiting Treatment Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IV Non-Small Cell Lung Cancer 1 1 Active Not Recruiting Treatment Stage IV Non-Small Cell Lung Cancer 1 1 Active Not Recruiting Treatment Unspecified Adult Solid Tumor, Protocol Specific 1 1 Completed Treatment Advanced Non-Small Cell Lung Cancer / Lung Cancer, Non-Small Cell 1 1 Completed Treatment Advanced Solid Tumors 1 1 Completed Treatment Advanced Solid Tumours / Cancers / Lung Cancer, Non-Small Cell 1 1 Completed Treatment Cancer, Advanced 2 1 Completed Treatment Cancer, Breast / Cancer, Ovarian / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Stomach / Prostate Cancer 1 1 Completed Treatment Cancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Mesothelioma / Prostate Cancer / Sarcomas 1 1 Completed Treatment Cancer, Ovarian / Cervical Cancers / Endometrial Cancers / Lung Cancers 1 1 Completed Treatment Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer 1 1 Completed Treatment Cancers 3 1 Completed Treatment Cancers / Metastases 1 1 Completed Treatment Carcinoma NOS / Lung Cancers / Non-Small Cell Lung 1 1 Completed Treatment Central Nervous System Lymphoma 1 1 Completed Treatment Esophageal Cancers 1 1 Completed Treatment Head and Neck Carcinoma 2 1 Completed Treatment Inoperable Non Small Cell Lung Cancer 1 1 Completed Treatment Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV 1 1 Completed Treatment Malignant Lymphomas / Tumors, Solid 1 1 Completed Treatment Mesothelioma 2 1 Completed Treatment Neoplasms 4 1 Completed Treatment Neoplasms, Malignant 1 1 Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 6 1 Completed Treatment Non-Squamous Non-Small Cell Lung Cancer 1 1 Completed Treatment Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 1 Completed Treatment Solid Cancers 1 1 Completed Treatment Tumors, Solid 2 1 Completed Treatment Unspecified Adult Solid Tumor 1 1 Completed Treatment Unspecified Adult Solid Tumor, Protocol Specific 4 1 Completed Treatment Unspecified Childhood Solid Tumor, Protocol Specific 1 1 Not Yet Recruiting Treatment Cancer, Advanced / Lung Cancers / Metastatic Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Neoplasm of Lung / Squamous Cell Carcinoma of Lung 1 1 Not Yet Recruiting Treatment Carcinoma of the Lungs / Lungcancer 1 1 Not Yet Recruiting Treatment Stage I Pleural Malignant Mesothelioma AJCC v7 / Stage IA Pleural Malignant Mesothelioma AJCC v7 / Stage IB Pleural Malignant Mesothelioma AJCC v7 / Stage II Pleural Malignant Mesothelioma AJCC v7 / Stage III Pleural Malignant Mesothelioma AJCC v7 1 1 Recruiting Other Mesothelioma 1 1 Recruiting Treatment Advanced Cancers 1 1 Recruiting Treatment Advanced Malignancies / Cancer, Advanced 1 1 Recruiting Treatment Advanced Non-Small Cell Lung Cancer / KRAS Gene Mutation / Lung Cancers 1 1 Recruiting Treatment Advanced thymic carcinoma / Bladder Cancers / Cancer, Ovarian / Mesothelioma / Non-Small-Cell Lung Carcinoma (NSCLC) / Peritoneal Cancer / Thymus Cancer / Uterine Cervical Cancer 1 1 Recruiting Treatment Cancer, Advanced / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Non-Small-Cell Lung Carcinoma (NSCLC) 1 1 Recruiting Treatment Cancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Malignant Neoplasm of Pancreas / Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors 1 1 Recruiting Treatment Cancer, Breast / Neoplasms Metastasis / Neoplasms, Colorectal 1 1 Recruiting Treatment Head and Neck Carcinoma / Salivary Gland Tumors 1 1 Recruiting Treatment Metastatic Malignant Neoplasm in the Brain / Stage IIIA Large Cell Lung Carcinoma / Stage IIIA Large Cell Lung Carcinoma AJCC v7 / Stage IIIA Lung Adenocarcinoma / Stage IIIA Lung Adenocarcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Large Cell Lung Carcinoma / Stage IIIB Large Cell Lung Carcinoma AJCC v7 / Stage IIIB Lung Adenocarcinoma / Stage IIIB Lung Adenocarcinoma AJCC v7 / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Large Cell Lung Carcinoma / Stage IV Large Cell Lung Carcinoma AJCC v7 / Stage IV Lung Adenocarcinoma / Stage IV Lung Adenocarcinoma AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 1 1 Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 1 Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 3 1 Recruiting Treatment Oncology, Medical 1 1 Recruiting Treatment Pleural Mesotheliomas 1 1 Recruiting Treatment Stage IV Lung Adenocarcinoma 1 1 Terminated Treatment Advanced Solid Malignancies / Cancers / Tumors, Solid 1 1 Terminated Treatment Malignant Lymphomas 1 1 Terminated Treatment Malignant Neoplasm of Pancreas 1 1 Terminated Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 3 1 Terminated Treatment Nonsmall Cell Lung Cancer Stage III / Nonsquamous Nonsmall Cell Neoplasm of Lung 1 1 Withdrawn Treatment Advanced Solid Tumors 1 1 Withdrawn Treatment Cancers / Neoplasms / Tumors 1 1 Withdrawn Treatment Lung Cancers 1 1 Withdrawn Treatment Malignant Pleural Mesothelioma (MPM) 1 1 Withdrawn Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Active Not Recruiting Treatment Advanced Malignant Mesothelioma / Epithelioid Mesothelioma / Pleural Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatoid Mesothelioma 1 1, 2 Active Not Recruiting Treatment Malignant Pleural Mesothelioma (MPM) / Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Active Not Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 1, 2 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Completed Treatment Advanced Carcinoma / Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Completed Treatment Cancer, Advanced / Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Completed Treatment Cancer, Breast 1 1, 2 Completed Treatment Cancer, Ovarian / Primary Peritoneal Cancer 1 1, 2 Completed Treatment Colorectal Cancers 1 1, 2 Completed Treatment Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer 1 1, 2 Completed Treatment Lung Cancers / Non-Small-Cell Lung Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) 1 1, 2 Completed Treatment Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific 2 1, 2 Completed Treatment Malignant Pleural Mesothelioma (MPM) 1 1, 2 Completed Treatment Malignant Pleural Mesothelioma (MPM) / Tumors, Solid 1 1, 2 Completed Treatment Malignant Pleural Mesotherioma 1 1, 2 Completed Treatment Neoplasm, Gastric 1 1, 2 Completed Treatment Neoplasms, Lung 1 1, 2 Completed Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 1, 2 Completed Treatment Non-Small-Cell Lung Cancer (NSCLC) 1 1, 2 Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 6 1, 2 Completed Treatment Rectal Carcinoma 1 1, 2 Completed Treatment Transitional Cell Carcinoma 1 1, 2 Completed Treatment Urologic Neoplasms 1 1, 2 Recruiting Treatment Advanced Malignant Solid Neoplasm / Advanced Peritoneal Malignant Mesothelioma / Advanced Pleural Malignant Mesothelioma / Advanced thymic carcinoma / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Peritoneal Malignant Mesothelioma / Recurrent Pleural Malignant Mesothelioma / Recurrent Solid Neoplasm / Solid Neoplasms / Stage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage III Ovarian Cancer / Stage III Pleural Malignant Mesothelioma AJCC v7 / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIC Ovarian Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IV Ovarian Cancer / Stage IV Pleural Malignant Mesothelioma AJCC v7 / Stage IV Pleural Mesothelioma / Unresectable Solid Neoplasm 1 1, 2 Recruiting Treatment Advanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC) 1 1, 2 Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 2 1, 2 Recruiting Treatment To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy 1 1, 2 Terminated Treatment Cancer, Breast / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific 1 1, 2 Terminated Treatment Carcinoma, Small Cell / Lung Cancer Small Cell Lung Cancer (SCLC) 1 1, 2 Terminated Treatment Head and Neck Carcinoma 1 1, 2 Terminated Treatment Mesothelioma 1 1, 2 Terminated Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 3 1, 2 Unknown Status Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 2 1, 2 Withdrawn Treatment Malignant Pleural Mesothelioma (MPM) 1 2 Active Not Recruiting Treatment Brain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers 1 2 Active Not Recruiting Treatment Cancers 1 2 Active Not Recruiting Treatment Lung Cancers 3 2 Active Not Recruiting Treatment Lung Cancers / Neoplasms Metastasis 1 2 Active Not Recruiting Treatment Malignant Pleural Mesothelioma (MPM) 1 2 Active Not Recruiting Treatment Mesothelioma, Malignant 2 2 Active Not Recruiting Treatment Metastatic Breast Cancer (MBC) 1 2 Active Not Recruiting Treatment Metastatic Colorectal Cancers 1 2 Active Not Recruiting Treatment Metastatic Non-Small Cell Lung Cancer / Nonsquamous Nonsmall Cell Neoplasm of Lung 1 2 Active Not Recruiting Treatment Non Small Cell Lung Carcinoma (NSCLC) 1 2 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 5 2 Active Not Recruiting Treatment Nonsquamous Nonsmall Cell Neoplasm of Lung 1 2 Active Not Recruiting Treatment Recurrent Non-small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 2 Approved for Marketing Not Available Mesothelioma 1 2 Completed Not Available Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Nonsquamous Non-Small Cell Neoplasm of Lung 1 2 Completed Diagnostic Cancers 1 2 Completed Prevention Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy 1 2 Completed Treatment Adenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease 1 2 Completed Treatment Adenocarcinoma of the Lung 1 2 Completed Treatment Adenocarcinoma of the Lung / Metastatic Brain Tumors 1 2 Completed Treatment Adenocarcinomas 1 2 Completed Treatment Adenocarcinomas / Non-Small-Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Advanced Gastric Carcinoma 1 2 Completed Treatment Advanced Non Small Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Advanced Non-Small Cell Lung Cancer 1 2 Completed Treatment Advanced Non-Squamous Non-Small Cell Lung Cancer 1 2 Completed Treatment Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer 1 2 Completed Treatment Breast Neoplasms, Male / Cancer, Breast / Ductal Carcinoma 1 2 Completed Treatment Cancer of the Endometrium / Endometrial Cancers / Endometrial Carcinoma / Endometrium Cancer / Genital Neoplasms, Female / Genitourinary tract neoplasm / Neoplasms / Neoplasms by Site / Neoplasms, Endometrial / Uterine Neoplasms 1 2 Completed Treatment Cancer, Breast 6 2 Completed Treatment Cancer, Breast / Neoplasms Metastasis 1 2 Completed Treatment Cancer, Breast / Neoplasms, Breast 1 2 Completed Treatment Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer 1 2 Completed Treatment Cancer, Ovarian / Peritoneal Cancer 1 2 Completed Treatment Cancer, Ovarian / Primary Peritoneal Cavity Cancer 1 2 Completed Treatment Cancers 1 2 Completed Treatment Carcinoma NOS / Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Completed Treatment Carcinoma, Small Cell 1 2 Completed Treatment Cervical Cancers 2 2 Completed Treatment Cervical Intraepithelial Neoplasia (CIN) / Genital Neoplasms, Female / Uterine Neoplasms 1 2 Completed Treatment Choriocarcinoma / Hydatidiform Mole / Trophoblastic Neoplasms / Uterine Neoplasms 1 2 Completed Treatment Colorectal Cancers 2 2 Completed Treatment Endometrial Cancers 1 2 Completed Treatment Ependymomas / Ewing's Sarcoma (ES) / Medulloblastomas / Neuroblastoma (Measurable Disease) / Neuroblastoma (Metaiodobenzylguanidine / Non-brainstem High-grade Glioma / Positive Evaluable) / Rhabdomyosarcomas / Sarcoma, Osteogenic 1 2 Completed Treatment Head and Neck Carcinoma 4 2 Completed Treatment Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer 1 2 Completed Treatment Liver Cancer 1 2 Completed Treatment Lung Cancer, Non-Small Cell 1 2 Completed Treatment Lung Cancers 21 2 Completed Treatment Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC) 1 2 Completed Treatment Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) 2 2 Completed Treatment Malignant Neoplasm of Pancreas 1 2 Completed Treatment Malignant Neoplasm of Stomach 2 2 Completed Treatment Malignant Pleural Mesothelioma (MPM) 2 2 Completed Treatment Mesothelioma 4 2 Completed Treatment Mesothelioma, Malignant 2 2 Completed Treatment Mesothelioma / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Completed Treatment Metastatic Colorectal Cancers 2 2 Completed Treatment Metastatic Non-squamous Non Small Cell Lung Cancer 1 2 Completed Treatment Nasopharyngeal Neoplasms 1 2 Completed Treatment Neoplasm Metastases / Urologic Neoplasms 1 2 Completed Treatment Neoplasms, Breast 1 2 Completed Treatment Neoplasms, Gastrointestinal 1 2 Completed Treatment Neoplasms, Head and Neck 2 2 Completed Treatment Neoplasms, Lung 1 2 Completed Treatment Neoplasms, Ovarian / Primary Peritoneal Cancer 1 2 Completed Treatment Neuroendocrine Tumors 1 2 Completed Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 2 Completed Treatment Non-Small-Cell Lung Cancer (NSCLC) 5 2 Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 33 2 Completed Treatment Non-Squamous Non-Small Cell Lung Cancer 2 2 Completed Treatment Ovarian Carcinoma / Primary Peritoneal Carcinoma 1 2 Completed Treatment Pleural Neoplasms 1 2 Completed Treatment Previous Treated Metastatic Non-small Cell Lung Cancer 1 2 Completed Treatment Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer 1 2 Completed Treatment Prostate Cancer 1 2 Completed Treatment Rectal Neoplasms 1 2 Completed Treatment Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 2 Completed Treatment Recurrent Non-small Cell Lung Cancer 1 2 Completed Treatment Sarcoma, Osteogenic 1 2 Completed Treatment Sarcomas 2 2 Completed Treatment Soft Tissue Sarcoma (STS) 1 2 Completed Treatment Advanced thymic carcinoma / Thymic Carcinoma 1 2 Completed Treatment Transitional Cell Carcinoma 1 2 Completed Treatment Urologic Neoplasms 1 2 Not Yet Recruiting Treatment Adenocarcinoma of the Lung 1 2 Not Yet Recruiting Treatment Advanced Non-squamous Non-small-cell Lung Cancer 1 2 Not Yet Recruiting Treatment Colo-rectal Cancer 1 2 Not Yet Recruiting Treatment EGFR Gene Mutations / Nonsmall Cell Lung Cancer 1 2 Not Yet Recruiting Treatment Lung Cancers 1 2 Not Yet Recruiting Treatment Malignant Pleural Mesothelioma (MPM) 1 2 Not Yet Recruiting Treatment Metastatic Brain Tumors 1 2 Not Yet Recruiting Treatment Non-Small-Cell Lung Cancer (NSCLC) 1 2 Not Yet Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 4 2 Recruiting Diagnostic Stage IIIA Non-Small Cell Lung Cancer 1 2 Recruiting Treatment Adenocarcinoma of the Lung 1 2 Recruiting Treatment Adenocarcinoma of the Lung / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 2 Recruiting Treatment Adenocarcinomas / Carcinoma, Large Cell / Heregulin / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC) 1 2 Recruiting Treatment Adenocarcinomas / Neoplasms, Lung 1 2 Recruiting Treatment Advanced NSCLC 1 2 Recruiting Treatment Advanced Stage IIIB / High Thymidylate Synthase Expression / Non-Small-Cell Lung Carcinoma (NSCLC) / Secondary 1 2 Recruiting Treatment Bevacizumab / Metastatic Brain Tumors / Non Squamous Non-small Cell Lung Cancer 1 2 Recruiting Treatment Bladder Cancers / Urothelial Cancer 1 2 Recruiting Treatment Cancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer 1 2 Recruiting Treatment Carcinoma, Non-squamous Non-small-cell Lung 1 2 Recruiting Treatment Colorectal Cancers 1 2 Recruiting Treatment EGFR Mutations / Metastatic Brain Tumors / Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Recruiting Treatment Lung Cancers 2 2 Recruiting Treatment Malignant Pleural Mesothelioma (MPM) 1 2 Recruiting Treatment Medulloblastomas 1 2 Recruiting Treatment Mesothelioma 2 2 Recruiting Treatment Metastatic Non-Small Cell Lung Cancer 1 2 Recruiting Treatment Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) 1 2 Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 8 2 Recruiting Treatment Non-small-cell Lung Cancer With Somatic EGFR Mutations 1 2 Recruiting Treatment Nonsmall Cell Lung Cancer 1 2 Recruiting Treatment Squamous Cell Carcinoma of Lung 1 2 Recruiting Treatment Stage IV Non-Small Cell Lung Cancer 1 2 Suspended Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Terminated Diagnostic Malignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas 1 2 Terminated Treatment Adenocarcinoma of the Cervix / Adenosquamous Cell Carcinoma of the Cervix 1 2 Terminated Treatment Cancer, Ovarian / Peritoneal Cancer 1 2 Terminated Treatment Carcinoma, Small Cell 1 2 Terminated Treatment Esophageal Cancers 1 2 Terminated Treatment Gestational Trophoblastic Disease 1 2 Terminated Treatment Head and Neck Carcinoma 1 2 Terminated Treatment Lung Cancer - Non Small Cell 1 2 Terminated Treatment Lung Cancer Small Cell Lung Cancer (SCLC) 4 2 Terminated Treatment Lung Cancers 6 2 Terminated Treatment Lung Cancers / Metastatic Cancers 1 2 Terminated Treatment Malignant Neoplasm of Pancreas 1 2 Terminated Treatment Mesothelioma, Malignant 1 2 Terminated Treatment Mesothelioma / Pleural Mesotheliomas 1 2 Terminated Treatment Metastatic Colorectal Cancers 1 2 Terminated Treatment Neoplasms, Esophageal 1 2 Terminated Treatment Neoplasms, Lung 1 2 Terminated Treatment Non Small Cell Lung Carcinoma (NSCLC) 1 2 Terminated Treatment Non-Small Cell Lung Carcinoma (NSCLC) 2 2 Terminated Treatment Non-Small-Cell Lung Cancer (NSCLC) 3 2 Terminated Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 9 2 Terminated Treatment Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer 1 2 Terminated Treatment Recurrent Non Small Cell Lung Cancer 1 2 Terminated Treatment Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 2 Terminated Treatment Renal Cell Adenocarcinoma 1 2 Unknown Status Treatment Advanced Non-Small Cell Lung Cancer 1 2 Unknown Status Treatment Malignant / Mesothelioma / Pleural 1 2 Unknown Status Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 8 2 Unknown Status Treatment Non-Small-Cell Lung Carcinoma (NSCLC) / Toxicity 1 2 Unknown Status Treatment Pleural Mesotheliomas 1 2 Unknown Status Treatment Squamous Cell Carcinoma of Head and Neck 1 2 Unknown Status Treatment Thyroid Cancers 1 2 Unknown Status Treatment Tumors, Central Nervous System 1 2 Unknown Status Treatment Untreated Advanced Non-Small Cell Lung Cancer 1 2 Withdrawn Treatment Advanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma 1 2 Withdrawn Treatment Cancer of Head and Neck 1 2 Withdrawn Treatment Esophagogastric Cancer 1 2 Withdrawn Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Withdrawn Treatment Primary Central Nervous System Lymphoma (PCNSL) 1 2 Withdrawn Treatment Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 2 Withdrawn Treatment Stage III Non-Small Cell Lung Cancer 1 2, 3 Active Not Recruiting Treatment Non-Small Cell Lung Cancer Recurrent / Non-Small-Cell Lung Carcinoma (NSCLC) / Progression of Non-small Cell Lung Cancer 1 2, 3 Completed Treatment Mesothelioma 1 2, 3 Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 2, 3 Not Yet Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 2, 3 Recruiting Treatment Mesothelioma 1 2, 3 Terminated Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Active Not Recruiting Prevention Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Active Not Recruiting Treatment Adenocarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Active Not Recruiting Treatment Advanced Non Small Cell Lung Cancer 1 3 Active Not Recruiting Treatment Advanced Non-Small Cell Lung Cancer 1 3 Active Not Recruiting Treatment Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Active Not Recruiting Treatment Lung Cancers 1 3 Active Not Recruiting Treatment Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Active Not Recruiting Treatment Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB 1 3 Active Not Recruiting Treatment NSCLC (Non-Small Cell Lung Cancer) 1 3 Active Not Recruiting Treatment Non Small Cell Lung Cancer (Squamous or Non Squamous) 1 3 Active Not Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 7 3 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC 1 3 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer 1 3 Active Not Recruiting Treatment Non-Squamous Non-Small Cell Lung Cancer 1 3 Active Not Recruiting Treatment Stage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 1 3 Active Not Recruiting Treatment Stage IV or Recurrent Non-Small Cell Lung Cancer 1 3 Completed Treatment Lung Cancer Small Cell Lung Cancer (SCLC) 1 3 Completed Treatment Lung Cancers 1 3 Completed Treatment Mesothelioma 1 3 Completed Treatment Mesothelioma, Malignant 1 3 Completed Treatment Neoplasm Metastases / Neoplasms, Pancreatic 1 3 Completed Treatment Neoplasms, Head and Neck 1 3 Completed Treatment Non Small Cell Lung Carcinoma (NSCLC) 2 3 Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 14 3 Completed Treatment Non-Squamous Non-Small Cell Lung Cancer 3 3 Enrolling by Invitation Treatment Cancers 1 3 Enrolling by Invitation Treatment EGFR Gene Mutations 1 3 Not Yet Recruiting Treatment Carcinoma, Bronchogenic / Chronic Lung Diseases / Neoplasm, Bronchial / Neoplasms by Site / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms 1 3 Not Yet Recruiting Treatment Carcinoma，Non-Small-Cell Lung / Lung Carcinomas, Non-Small-Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer 1 3 Not Yet Recruiting Treatment Malignant Hydrothorax / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Not Yet Recruiting Treatment Non-Small-Cell Lung Cancer (NSCLC) 1 3 Not Yet Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 2 3 Recruiting Other Adenocarcinoma of Lung Metastatic to Brain / Bevacizumab / Brain Radiotherapy / Cerebral Metastases / Cerebral Radiotherapy / Metastatic Non-Small Cell Lung Cancer / Non Epidermoid / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Recruiting Treatment Bladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer 1 3 Recruiting Treatment Carcinoma，Non-Small-Cell Lung 1 3 Recruiting Treatment Chemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms 1 3 Recruiting Treatment First Line Non-Small Cell Lung Cancer 1 3 Recruiting Treatment Mesothelioma 2 3 Recruiting Treatment Metastatic Non-Squamous Non-Small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Recruiting Treatment Neoplasms, Lung 1 3 Recruiting Treatment Non Small Cell Lung Cancer NSCLC / Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Recruiting Treatment Non Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC 2 3 Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 3 Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 7 3 Recruiting Treatment Non-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1 3 Recruiting Treatment Oligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer（NSCLC） 1 3 Terminated Treatment Lung Cancers 1 3 Terminated Treatment Lung Cancers / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Pulmonary Neoplasms 1 3 Terminated Treatment Non Small Cell Lung Carcinoma (NSCLC) 1 3 Terminated Treatment Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 3 Unknown Status Treatment Lung Cancers 1 3 Unknown Status Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 3 Unknown Status Treatment Non-squamous Nonsmall Cell Neoplasm of Lung 1 4 Completed Treatment Locally Advanced Malignant Neoplasm 1 4 Completed Treatment Non-Small-Cell Lung Cancer (NSCLC) 1 4 Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 2 4 Not Yet Recruiting Treatment Adenocarcinoma of the Lung 1 4 Recruiting Treatment Adenocarcinoma of the Lung 1 4 Recruiting Treatment Adenocarcinomas / EGFR Positive Non-small Cell Lung Cancer 2 4 Recruiting Treatment Non-Small-Cell Lung Cancer (NSCLC) 1 Not Available Completed Not Available Neoplasms, Lung 1 Not Available Completed Not Available Non-Small-Cell Lung Carcinoma (NSCLC) 1 Not Available Completed Treatment Hypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC) 1 Not Available Completed Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 Not Available Terminated Treatment Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer 1 Not Available Unknown Status Screening Non-Small-Cell Lung Carcinoma (NSCLC) 1 Not Available Unknown Status Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1
Pharmacoeconomics Manufacturers Packagers Dosage forms Form Route Strength Injection, powder, lyophilized, for solution Intravenous 100 mg/4mL Injection, powder, lyophilized, for solution Intravenous 500 mg/20mL Powder, for solution Intravenous 100 mg Powder, for solution Intravenous 500 mg Injection, powder, for solution Intravenous 100 mg Injection, powder, for solution Intravenous 500 mg Powder, for solution Intravenous 1000 mg Injection, powder, for solution Intravenous 000 mg Injection, powder, for solution Intravenous 1000 mg
Prices Unit description Cost Unit Alimta 500 mg Solution Vial 3154.94USD vial Alimta 500 mg vial 3033.6USD vial Alimta 100 mg vial 606.72USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Patent Number Pediatric Extension Approved Expires (estimated) US5217974 No 1994-03-29 2011-03-29 US CA2400155 No 2009-09-15 2021-02-12 Canada CA1340794 No 1999-10-19 2016-10-19 Canada US7772209 Yes 2002-05-24 2022-05-24 US US5344932 Yes 1997-01-24 2017-01-24 US
Properties State Solid Experimental Properties Property Value Source logP -1.5 Not Available
Predicted Properties Predicted ADMET features Property Value Probability Human Intestinal Absorption + 0.6997 Blood Brain Barrier + 0.7542 Caco-2 permeable - 0.819 P-glycoprotein substrate Substrate 0.5 P-glycoprotein inhibitor I Non-inhibitor 0.9729 P-glycoprotein inhibitor II Non-inhibitor 0.9825 Renal organic cation transporter Non-inhibitor 0.8923 CYP450 2C9 substrate Non-substrate 0.7547 CYP450 2D6 substrate Non-substrate 0.8204 CYP450 3A4 substrate Non-substrate 0.6051 CYP450 1A2 substrate Non-inhibitor 0.912 CYP450 2C9 inhibitor Non-inhibitor 0.8938 CYP450 2D6 inhibitor Non-inhibitor 0.9117 CYP450 2C19 inhibitor Non-inhibitor 0.8844 CYP450 3A4 inhibitor Non-inhibitor 0.8253 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9508 Ames test Non AMES toxic 0.8528 Carcinogenicity Non-carcinogens 0.964 Biodegradation Not ready biodegradable 0.8296 Rat acute toxicity 2.5023 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9624 hERG inhibition (predictor II) Non-inhibitor 0.8718
ADMET data is predicted using
admetSAR , a free tool for evaluating chemical ADMET properties. (
23092397 )
Spectra Mass Spec (NIST) Not Available Spectra Taxonomy Description This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. Kingdom Organic compounds Super Class Organic acids and derivatives Class Carboxylic acids and derivatives Sub Class Amino acids, peptides, and analogues Direct Parent Glutamic acid and derivatives Alternative Parents N-acyl-alpha amino acids / Hippuric acids / Pyrrolo[2,3-d]pyrimidines / Benzoyl derivatives / Pyrimidones / Aminopyrimidines and derivatives / Substituted pyrroles / Dicarboxylic acids and derivatives / Vinylogous amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids / Azacyclic compounds / Carboxylic acids / Carbonyl compounds / Hydrocarbon derivatives / Organic oxides / Organopnictogen compounds / Primary amines show 9 moreSubstituents Glutamic acid or derivatives / Hippuric acid or derivatives / Hippuric acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Pyrrolopyrimidine / Benzamide / Pyrrolo[2,3-d]pyrimidine / Benzoic acid or derivatives / Benzoyl / Pyrimidone / Aminopyrimidine / Dicarboxylic acid or derivatives / Benzenoid / Monocyclic benzene moiety / Pyrimidine / Substituted pyrrole / Heteroaromatic compound / Vinylogous amide / Pyrrole / Amino acid / Secondary carboxylic acid amide / Carboxamide group / Azacycle / Carboxylic acid / Organoheterocyclic compound / Organic nitrogen compound / Amine / Carbonyl group / Hydrocarbon derivative / Organic oxide / Organopnictogen compound / Organic oxygen compound / Primary amine / Organooxygen compound / Organonitrogen compound / Aromatic heteropolycyclic compound show 27 moreMolecular Framework Aromatic heteropolycyclic compounds External Descriptors pyrrolopyrimidine, N-acyl-L-glutamic acid (CHEBI:63616 ) 
